ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
AstraZeneca has contracted with Lonza to manufacture its antibody to prevent and treat COVID-19. A combination of two long-acting antibodies, AZD7442 is in Phase 1 clinical trials, and AstraZeneca anticipates starting Phase 3 trials by year’s end. Under the contract, Lonza, a Swiss pharmaceutical services firm, will produce the antibodies in a new facility at its Portsmouth, New Hampshire, biologics complex in the first half of 2021.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter